STARD4

Across TCGA pan-cancer cohorts, STARD4 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated STARD4 data layer compared with 26 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher STARD4 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated STARD4 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

LUAD, CCRCC, and LSCC are the cancer types where STARD4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	0.322	0.804	<.001	47	view →
CCRCC	OS	Median	III,IV	0.104	0.985	.014	18	view →
LSCC	DFS	Tertile	III,IV	0.556	1.000	.025	7	view →
UCEC	DFS	Tertile	II,III,IV	0.483	1.000	.040	4	view →
HNSC	DFS	Median	III,IV	1.000	0.892	.040	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

STARD4–LUAD (DFS)

Open the LUAD breakdown →